New dosing guidelines aim to cut cancer treatment disruptions for duffy null patients
NCT ID NCT07341867
First seen Jan 14, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests whether using special dosing guidelines for people with the Duffy null blood type can reduce or delay the need to lower or pause their cancer drugs, and lower the risk of fever from low white blood cells. It includes 90 adults with multiple myeloma or triple-negative breast cancer who are starting standard treatments. The study also compares their outcomes to people without the Duffy null trait and includes optional surveys about health experiences.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.